Bronchogen

Bioregulators Research compound (not approved for human use)

Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu) · also known as AEDL, Ala-Glu-Asp-Leu

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Bronchogen belongs to the short-peptide bioregulator family and is associated in that literature with bronchial and lung tissue. Published work is limited to cell, biophysical and animal experiments, and no human dosing trials establish an amount, route or schedule.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Phase	Dose	Volume	U-100 units
Standard	1 mg	0.15 mL	15
Higher	2 mg	0.3 mL	30

Frequency: Once daily, in 10- or 20-day courses (community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Proposed to bind DNA and histone tails and to shift expression of lung-lineage genes such as NKX2-1 and the secretoglobin genes in cell models; this mechanism is hypothesized rather than established.

Researched for

Studied in a rat model of chronic obstructive lung injury, where a month of peptide administration was reported to normalize bronchial epithelium and reduce neutrophilic inflammation.
Examined in vitro for DNA binding, including a calorimetry study showing it raised DNA melting temperature.
Described in reviews as a regulator of lung cell function and differentiation.

Notes

Sequence reporting is inconsistent in the literature: most sources give Ala-Glu-Asp-Leu (AEDL), but one abstract title lists Ala-Asp-Glu-Leu.
Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.

Sources

Last reviewed 2026-10-06.

Cartalax

Synthetic tripeptide bioregulator (Ala-Glu-Asp)

Cartalax is a three-residue peptide (alanine, glutamate, aspartate) studied by the Khavinson group in connection with cartilage and connective tissue.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)